Ascentage Pharma Announces Appointment of Han Li as Chief Financial Officer

Date | 2017.07.05

HONG KONG, Jul 5, 2017 /PRNewswire/ — Ascentage Pharma, a global clinical-stage biopharmaceutical company focused on apoptosis-targeted drug discovery and development, today announced the appointment of Han Li, Ph.D., as its Chief Financial Officer. Dr. Li has joined Ascentage Pharma’s senior executive team and will be responsible for the finance, corporate and business development. Dr. Li joins Ascentage from Bayer Pharma AG.


“We are delighted to have Han join our team. His extensive experience in drug discovery, pharmaceuticals strategic marketing, business development and equity research on Wall Street will serve well Ascentage for the next phase of corporate growth and development,” said Dajun Yang, M.D., Ph.D., Chairman and CEO of Ascentage. “We look forward to Han’s leadership in developing and executing financial strategy for Ascentage as we advance our product candidates in a fast pace.”


Dr. Li has over twenty years of experience in the biopharmaceutical industry and on Wall Street. Prior to Ascentage, he had worked in Strategic Marketing at Bayer Pharmaceuticals, responsible for Strategy and Portfolio Management and commercial development.  He had been actively involved in commercial launches of oncology drugs (Stivarga and Xofigo), and various BD&L activities (including Algeta Acquisition and Orion partnership). Before Bayer, Dr. Li had worked on Wall Street as a biotech analyst at Morgan Stanley, Suntrust Robinson Humphrey, and Stanford Financial Group.  He was top rated by the StarMine Analyst Ranking for earnings accuracy and stock recommendation of companies under coverage. Prior to that, he was a research scientist at Genentech in drug discovery and was a lead inventor of three international patents on novel cytokines.  Dr. Li holds a Ph.D. degree in Pharmacology from Boston University School of Medicine and an M.B.A. degree in Finance from University of California at Los Angeles.


“I am impressed with the robust drug discovery platform of Protein-Protein Interaction and science-driven culture at Ascentage.” commented Dr. Li, “I would like to contribute to the future expansion and growth of the Company with my combined experience in biopharma and Wall Street.”


About Ascentage Pharma

Ascentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases. Ascentage has world-leading proprietary Protein-Protein Interaction drug discovery technologies and holds over 100 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US, Australia and China and additional programs in preclinical stages.


The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP, Bcl-2/Bcl-xL and MDM2-p53, that regulate a tumor cell's programmed cell death program; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics. For more information, please visit